FR21C1042I2 - Modulateurs de transport nucleaire contenant de l'hydrazide et leurs utilisations - Google Patents

Modulateurs de transport nucleaire contenant de l'hydrazide et leurs utilisations

Info

Publication number
FR21C1042I2
FR21C1042I2 FR21C1042C FR21C1042C FR21C1042I2 FR 21C1042 I2 FR21C1042 I2 FR 21C1042I2 FR 21C1042 C FR21C1042 C FR 21C1042C FR 21C1042 C FR21C1042 C FR 21C1042C FR 21C1042 I2 FR21C1042 I2 FR 21C1042I2
Authority
FR
France
Prior art keywords
nuclear transport
containing hydrazide
transport modulators
modulators containing
hydrazide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1042C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karyopharm Therapeutics Inc
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of FR21C1042I1 publication Critical patent/FR21C1042I1/fr
Application granted granted Critical
Publication of FR21C1042I2 publication Critical patent/FR21C1042I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
FR21C1042C 2011-07-29 2021-09-15 Modulateurs de transport nucleaire contenant de l'hydrazide et leurs utilisations Active FR21C1042I2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161513428P 2011-07-29 2011-07-29
US201161513432P 2011-07-29 2011-07-29
US201261610178P 2012-03-13 2012-03-13
US201261653588P 2012-05-31 2012-05-31
US201261654651P 2012-06-01 2012-06-01
PCT/US2012/048319 WO2013019548A1 (fr) 2011-07-29 2012-07-26 Modulateurs de transport nucléaire contenant de l'hydrazide et leurs utilisations

Publications (2)

Publication Number Publication Date
FR21C1042I1 FR21C1042I1 (fr) 2021-11-19
FR21C1042I2 true FR21C1042I2 (fr) 2022-09-02

Family

ID=46634546

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1042C Active FR21C1042I2 (fr) 2011-07-29 2021-09-15 Modulateurs de transport nucleaire contenant de l'hydrazide et leurs utilisations

Country Status (35)

Country Link
US (8) US9079865B2 (fr)
EP (3) EP4234545A3 (fr)
JP (3) JP6005740B2 (fr)
KR (6) KR102022716B1 (fr)
CN (5) CN110372673B (fr)
AR (1) AR087342A1 (fr)
AU (6) AU2012290454B2 (fr)
BR (1) BR112014001934B1 (fr)
CA (1) CA2842362C (fr)
CL (2) CL2014000225A1 (fr)
CO (1) CO6960539A2 (fr)
CY (1) CY1119783T1 (fr)
DK (2) DK2736887T3 (fr)
EA (1) EA201490407A1 (fr)
ES (2) ES2655645T3 (fr)
FR (1) FR21C1042I2 (fr)
GE (1) GEP201706616B (fr)
HK (2) HK1198477A1 (fr)
HR (1) HRP20180014T1 (fr)
HU (2) HUE036058T2 (fr)
LT (2) LT2736887T (fr)
LU (1) LUC00219I2 (fr)
ME (1) ME02936B (fr)
MX (1) MX349712B (fr)
NL (1) NL301119I2 (fr)
NO (1) NO2021033I1 (fr)
PE (1) PE20141170A1 (fr)
PL (2) PL3333164T3 (fr)
PT (1) PT2736887T (fr)
RS (1) RS56823B1 (fr)
SI (1) SI2736887T1 (fr)
TW (1) TWI574957B (fr)
UA (1) UA115532C2 (fr)
WO (1) WO2013019548A1 (fr)
ZA (1) ZA201401223B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2542089B1 (fr) 2010-03-05 2017-01-18 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire et leurs utilisations
EP2665362B1 (fr) 2011-01-17 2016-03-30 Karyopharm Therapeutics, Inc. Modulateurs du transport nucléaire contenant des oléfines et leurs utilisations
BR112014001933A2 (pt) 2011-07-29 2017-02-21 Karyopharm Therapeutics Inc moduladores de transporte nuclear e usos dos mesmos
KR102022716B1 (ko) * 2011-07-29 2019-09-18 카리오팜 쎄라퓨틱스, 인코포레이티드 하이드라지드 함유 핵 수송 조절인자 및 이의 용도
US9649388B2 (en) 2012-01-18 2017-05-16 Bioneer Corporation Magnetic nanoparticle-samirna complex and method for preparing same
SI3404027T1 (sl) 2012-05-09 2020-08-31 Biogen Ma Inc. Modulatorji jedrnega transporta in njihova uporaba
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
WO2014144772A1 (fr) * 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Procédés de promotion de la cicatrisation d'une plaie à l'aide d'inhibiteurs de crm1
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
WO2014205393A1 (fr) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Modulateurs de transport nucléaire et leurs utilisations
DK3492455T3 (da) * 2013-06-21 2023-08-14 Karyopharm Therapeutics Inc 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer
ES2809481T3 (es) 2013-07-05 2021-03-04 Bioneer Corp Estructura de oligonucleótidos de tipo nanopartícula mejorada que tiene alta eficiencia y método para preparar la misma
WO2015002512A1 (fr) 2013-07-05 2015-01-08 (주)바이오니아 Arnsi spécifique du virus de la dengue, structure d'arn-oligo à double hélice comprenant un arnsi, et composition empêchant la prolifération du virus de la dengue comprenant la structure d'arn
KR20150006743A (ko) * 2013-07-09 2015-01-19 (주)바이오니아 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US9861615B2 (en) * 2013-11-28 2018-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of beta-thalassemias
EP3128008B1 (fr) 2014-04-04 2024-05-29 Bioneer Corporation Oligo-arn à double brin et composition pharmaceutique le comprenant pour la prévention ou le traitement de la fibrose ou de maladies respiratoires
SG10201808624VA (en) * 2014-08-15 2018-11-29 Karyopharm Therapeutics Inc Polymorphs of selinexor
EP3397633A1 (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire et leurs utilisations
WO2017117535A1 (fr) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Modulateurs de transport nucléaire et leurs utilisations
US11034675B2 (en) 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
EP3241830A1 (fr) 2016-05-04 2017-11-08 Bayer CropScience Aktiengesellschaft Derivés de bicycles condensés hétérocycliques utilisés comme pesticides
US11065230B2 (en) 2016-09-16 2021-07-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
WO2018129227A1 (fr) 2017-01-05 2018-07-12 Watson Laboratories Inc. Nouvelles formes cristallines de sélinexor et leur procédé de préparation
CN106831731B (zh) * 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
CN106831617A (zh) * 2017-01-17 2017-06-13 广州市闻皓生物科技有限公司 一种Selinexor中间体的合成工艺
WO2018191707A2 (fr) * 2017-04-13 2018-10-18 Brown University Régulateur nucléocytoplasmique de facteurs de transcription associés à l'autophagie
WO2019232724A1 (fr) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Composés en tant que modulateurs de transport nucléaire et leurs utilisations
CN108947982A (zh) * 2018-08-16 2018-12-07 刘璐 治疗非酒精性脂肪肝病的吡嗪衍生物、组合物和应用
WO2020092965A1 (fr) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 en tant que biomarqueur pour des traitements utilisant des inhibiteurs de xpo1
CN111606890A (zh) 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 含丙烯酰基的核转运调节剂及其用途
KR20210141936A (ko) 2019-03-20 2021-11-23 존슨 맛쎄이 퍼블릭 리미티드 컴파니 셀리넥서의 공결정 형태
MA55808A (fr) 2019-05-01 2022-03-09 Karyopharm Therapeutics Inc Procédé de préparation d'inhibiteurs de xpo1 et intermédiaires destinés à être utilisés dans la préparation d'inhibiteurs de xpo1
EP3808742A1 (fr) 2019-10-16 2021-04-21 Sandoz AG Polymorphe de selinexor
WO2021163338A1 (fr) 2020-02-11 2021-08-19 Karyopharm Therapeutics Inc. Inhibiteurs de xpo1 destinés à être utilisés dans le traitement du cancer
CA3171979A1 (fr) 2020-03-27 2021-09-30 Josep Bassaganya-Riera Ligands de plxdc2
WO2021202745A1 (fr) 2020-03-31 2021-10-07 Karyopharm Therapeutics Inc. Traitement du covid-19 à l'aide d'un composé sine
WO2021209563A1 (fr) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Composés destinés à être utilisés dans le traitement d'infections virales par un coronavirus associé au syndrome respiratoire
WO2021252905A1 (fr) 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Biomarqueurs pour la réponse à des inhibiteurs de l'exportine 1 chez des patients atteints d'un lymphome diffus à grandes cellules b
WO2021252874A1 (fr) 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Inhibiteurs de xpo1 destinés à être utilisés dans le traitement du cancer
WO2021252900A1 (fr) 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Biomarqueurs pour la réponse à des inhibiteurs de l'exportine 1 chez des patients atteints d'un myélome multiple
WO2022087218A1 (fr) 2020-10-21 2022-04-28 Karyopharm Therapeutics Inc. Forme cristalline de sélinexor
CN112679477B (zh) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 塞利尼索及其中间体的制备方法
WO2022143779A1 (fr) * 2020-12-29 2022-07-07 南京明德新药研发有限公司 Composé contenant un alcényle et son application
WO2022232417A1 (fr) 2021-04-28 2022-11-03 Karyopharm Therapeutics Inc. Biomarqueurs pour la réponse à des inhibiteurs de l'exportine 1 chez des patients atteints d'un myélome multiple
WO2022246065A1 (fr) 2021-05-19 2022-11-24 Karyopharm Therapeutics Inc. Biomarqueur calb1 utilisé dans le traitement de liposarcome dé-différencié à l'aide d'inhibiteurs de xpo1, tels que le sélinexor
CN116514773A (zh) * 2023-04-24 2023-08-01 重庆汉佩生物科技有限公司 一种Verdinexor(KPT-335)及其盐酸盐的合成方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
JPS5661360A (en) * 1979-10-25 1981-05-26 Teijin Ltd 1-substituted imidazole derivative and its preparation
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
IL97249A (en) * 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
CN1088062C (zh) 1994-11-23 2002-07-24 纽罗根公司 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
WO1997015567A1 (fr) 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh Heterocycles a 5 chainons, medicaments contenant ces composes, utilisation et procede de production correspondants
DE69736775T2 (de) 1996-04-04 2007-08-23 Shionogi & Co., Ltd. Cephemverbindungen und medikamente die diese verbindungen enthalten
CN1227229C (zh) 1996-04-25 2005-11-16 日产化学工业株式会社 乙烯衍生物和含有该衍生物的杀有害生物剂
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
AU2960599A (en) 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
EP1335898B1 (fr) 2000-09-29 2005-11-23 TopoTarget UK Limited Composes d'acide carbamique comprenant un enchainement amide comme inhibiteurs hdac
MXPA04002397A (es) 2001-09-14 2004-12-02 Methylgene Inc Inhibidores de histona deacetilasa.
WO2004037248A2 (fr) 2002-10-24 2004-05-06 Carex Sa Modulation de l'activite des recepteurs actives par les proliferateurs de peroxysomes
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
RU2337682C2 (ru) 2002-11-01 2008-11-10 Такеда Фармасьютикал Компани Лимитед Средство для профилактики или лечения невропатии
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
EP1599447A1 (fr) 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands modulant des recepteurs du type lxr
WO2005115990A1 (fr) 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. Composé de cinnamide
EP1780210A4 (fr) 2004-08-11 2009-06-10 Kyorin Seiyaku Kk Nouveau derive cyclique de l' acide aminobenzoique
WO2006019020A1 (fr) 2004-08-16 2006-02-23 Sankyo Company, Limited Urées de substitution
JPWO2006088246A1 (ja) 2005-02-18 2008-07-10 武田薬品工業株式会社 Ｇｐｒ３４受容体機能調節剤
KR101439557B1 (ko) 2005-11-15 2014-09-11 오츠카 세이야쿠 가부시키가이샤 옥사졸 화합물 및 제약 조성물
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
EA016464B1 (ru) 2006-03-09 2012-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Полициклические производные арилимидазола
EP2007720B1 (fr) 2006-04-07 2013-12-25 MethylGene Inc. Derives de benzamide utilises en tant qu'inhibiteurs de l'histone desacetylase
PL2014652T3 (pl) 2006-04-18 2015-02-27 Nippon Chemiphar Co Czynnik aktywujący receptor aktywowany przez proliferatory peroksysomów
DE102006024024A1 (de) * 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
WO2007147336A1 (fr) 2006-06-13 2007-12-27 Shanghai Institue Of Materia Medica, Chinese Academy Of Sciences Composés non nucléosidiques hétérocycliques, leur préparation, compositions pharmaceutiques, et leur utilisation en tant qu'agents antiviraux
CN100503571C (zh) 2006-07-12 2009-06-24 中国药科大学 四氢异喹啉类衍生物、其制备方法及其医药用途
AR063211A1 (es) 2006-07-27 2009-01-14 Amorepacific Corp Derivados de 3-(piridin-3-il)acrilamida y 3-(piridin-3-il)propionamida, un metodo para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con el receptor vaniloide.
KR101404360B1 (ko) 2006-09-05 2014-06-09 교와 핫꼬 기린 가부시키가이샤 이미다졸 유도체
EP1939180A1 (fr) 2006-12-20 2008-07-02 sanofi-aventis Hétéroarylacrylamides et leur utilisation en tant que médicament pour la stimulation de l'expression de la synthase NO endotheliale
EP1942104A1 (fr) 2006-12-20 2008-07-09 sanofi-aventis Hétéroarylcyclopropanecarboxamide et leur utilisation pharmaceutique
US7795457B2 (en) 2007-02-26 2010-09-14 Kosan Biosciences Incorporated Carbamate compounds
EP2003118A1 (fr) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Dérivés d'acides de cannelle en tant que modulateurs du récepteur EP2
EP2323737A2 (fr) 2008-08-08 2011-05-25 Synta Pharmaceuticals Corp. Composés de triazole qui modulent l'activité hsp90
MX2012000434A (es) 2009-07-09 2012-04-11 Crescendo Therapeutics Llc Metodo de sanacion de herida y modulacion de cicatriz.
WO2011069039A1 (fr) 2009-12-04 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Composés d'hydrazone et de diacylhydrazine, et leurs procédés d'utilisation
EP2542089B1 (fr) 2010-03-05 2017-01-18 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire et leurs utilisations
EP2665362B1 (fr) 2011-01-17 2016-03-30 Karyopharm Therapeutics, Inc. Modulateurs du transport nucléaire contenant des oléfines et leurs utilisations
BR112014001933A2 (pt) 2011-07-29 2017-02-21 Karyopharm Therapeutics Inc moduladores de transporte nuclear e usos dos mesmos
KR102022716B1 (ko) * 2011-07-29 2019-09-18 카리오팜 쎄라퓨틱스, 인코포레이티드 하이드라지드 함유 핵 수송 조절인자 및 이의 용도
WO2013020024A2 (fr) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Composés de maléimide et méthodes de traitement
SI3404027T1 (sl) 2012-05-09 2020-08-31 Biogen Ma Inc. Modulatorji jedrnega transporta in njihova uporaba
WO2014144772A1 (fr) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Procédés de promotion de la cicatrisation d'une plaie à l'aide d'inhibiteurs de crm1
WO2014152263A1 (fr) 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Modulateurs de transport nucléaire contenant une exo-oléfine et leurs utilisations
DK3492455T3 (da) 2013-06-21 2023-08-14 Karyopharm Therapeutics Inc 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer
WO2014205393A1 (fr) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Modulateurs de transport nucléaire et leurs utilisations
WO2015073908A1 (fr) 2013-11-15 2015-05-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Procédé de sélection d'un schéma de traitement du cancer
CN105294682B (zh) 2014-07-26 2017-07-07 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
SG10201808624VA (en) 2014-08-15 2018-11-29 Karyopharm Therapeutics Inc Polymorphs of selinexor
WO2017117535A1 (fr) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Modulateurs de transport nucléaire et leurs utilisations
EP3397633A1 (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire et leurs utilisations
US11034675B2 (en) 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
JP6765198B2 (ja) 2016-03-10 2020-10-07 パナソニック株式会社 潜熱蓄熱材及びそれを用いる蓄熱システム
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
WO2018129227A1 (fr) 2017-01-05 2018-07-12 Watson Laboratories Inc. Nouvelles formes cristallines de sélinexor et leur procédé de préparation

Also Published As

Publication number Publication date
CN110372672A (zh) 2019-10-25
AU2020203121A1 (en) 2020-05-28
JP6005740B2 (ja) 2016-10-12
ZA201401223B (en) 2022-03-30
JP2018111713A (ja) 2018-07-19
SI2736887T1 (en) 2018-04-30
KR20210083380A (ko) 2021-07-06
HK1198477A1 (en) 2015-05-08
EP3333164A1 (fr) 2018-06-13
NL301119I2 (nl) 2021-09-15
AU2022203265A1 (en) 2022-06-02
CN110372673B (zh) 2023-10-03
HRP20180014T1 (hr) 2018-04-20
US11787771B2 (en) 2023-10-17
US20200339521A1 (en) 2020-10-29
JP6675431B2 (ja) 2020-04-01
US20150274698A1 (en) 2015-10-01
US9714226B2 (en) 2017-07-25
CY1119783T1 (el) 2018-06-27
RS56823B1 (sr) 2018-04-30
CN106083827A (zh) 2016-11-09
HUS2100030I1 (hu) 2021-09-28
EP4234545A3 (fr) 2023-09-06
PL3333164T3 (pl) 2023-12-18
ME02936B (fr) 2018-04-20
HK1256745A1 (zh) 2019-10-04
KR20240060688A (ko) 2024-05-08
LUC00219I2 (fr) 2022-10-07
KR102136768B1 (ko) 2020-07-23
HUE036058T2 (hu) 2018-06-28
US10544108B2 (en) 2020-01-28
EP2736887B1 (fr) 2017-10-18
CO6960539A2 (es) 2014-05-30
EP3333164B1 (fr) 2023-06-07
DK3333164T3 (da) 2023-09-18
KR20200088518A (ko) 2020-07-22
EA201490407A1 (ru) 2014-05-30
PT2736887T (pt) 2018-01-15
CN106083827B (zh) 2019-09-17
CN110372672B (zh) 2023-09-29
MX349712B (es) 2017-08-09
AU2016210682A1 (en) 2016-08-18
ES2954991T3 (es) 2023-11-28
US9079865B2 (en) 2015-07-14
CA2842362C (fr) 2020-06-16
LT2736887T (lt) 2018-02-12
NO2021033I1 (no) 2021-09-06
AR087342A1 (es) 2014-03-19
US8999996B2 (en) 2015-04-07
AU2016210682B2 (en) 2018-04-19
LTPA2021007I1 (fr) 2021-08-25
JP2017036287A (ja) 2017-02-16
KR20230042129A (ko) 2023-03-27
NZ621904A (en) 2016-05-27
NZ719623A (en) 2017-12-22
US20160304472A1 (en) 2016-10-20
DK2736887T3 (en) 2018-01-02
US20140364408A1 (en) 2014-12-11
US9206158B2 (en) 2015-12-08
CL2014000225A1 (es) 2014-12-05
JP2014521652A (ja) 2014-08-28
GEP201706616B (en) 2017-02-10
TWI574957B (zh) 2017-03-21
US11034660B2 (en) 2021-06-15
CN110372673A (zh) 2019-10-25
KR20190045399A (ko) 2019-05-02
AU2024202868A1 (en) 2024-05-23
ES2655645T3 (es) 2018-02-21
EP2736887A1 (fr) 2014-06-04
BR112014001934B1 (pt) 2020-12-15
BR112014001934A2 (pt) 2017-02-21
AU2020203121B2 (en) 2022-02-17
FR21C1042I1 (fr) 2021-11-19
LTC2736887I2 (fr) 2022-10-25
JP6309057B2 (ja) 2018-04-11
KR20140066179A (ko) 2014-05-30
PL2736887T3 (pl) 2018-03-30
CN103874690B (zh) 2016-07-06
NL301119I1 (fr) 2021-08-04
AU2018202441B2 (en) 2020-02-13
CN117229268A (zh) 2023-12-15
TW201311666A (zh) 2013-03-16
WO2013019548A1 (fr) 2013-02-07
AU2012290454A1 (en) 2014-03-20
PE20141170A1 (es) 2014-09-16
US10173987B2 (en) 2019-01-08
US20190330164A1 (en) 2019-10-31
KR102022716B1 (ko) 2019-09-18
US20180127384A1 (en) 2018-05-10
CL2015001257A1 (es) 2015-09-21
AU2012290454B2 (en) 2016-05-05
AU2018202441A1 (en) 2018-04-26
MX2014001181A (es) 2014-07-14
CN103874690A (zh) 2014-06-18
UA115532C2 (uk) 2017-11-27
US20140235653A1 (en) 2014-08-21
CA2842362A1 (fr) 2013-02-07
US20220073478A1 (en) 2022-03-10
EP4234545A2 (fr) 2023-08-30

Similar Documents

Publication Publication Date Title
FR21C1042I2 (fr) Modulateurs de transport nucleaire contenant de l'hydrazide et leurs utilisations
ZA202004892B (en) Nuclear transport modulators and uses thereof
FR23C1019I2 (fr) Anticorps anti-complément c1s et utilisations de ceux-ci
HK1198478A1 (en) Nuclear transport modulators and uses thereof
DK2801283T3 (da) Rygsækramme- og taskesystem
FR2975869B1 (fr) Composition de preservation d'organe et utilisations
FR2976579B1 (fr) Epaississants non ioniques associatifs contenant des alkyls cyclohexylols, formulations les contenant et leurs utilisations
EP2845112A4 (fr) Mémoire répartie basée sur un maillage et architecture informatique
FR2986520B3 (fr) Enrouleur de tuyau et agencement d'enrouleur de tuyau
FR2982277B1 (fr) Cassette d'expression inductible et ses utilisations
BR112014004928A2 (pt) "conjunto e método de contenção de um poço "
FR2992531B1 (fr) Dispositif de conditionnement et d'application
FR2955741B1 (fr) Composition herbicide et utilisations
FR2955772B1 (fr) Peptides antimicrobiens et leurs utilisations en therapeutique
FR3013731B1 (fr) Variants d'endoglucanases a activite amelioree et leurs utilisations
FR3013732B1 (fr) Variants d'endoglucanases a activite amelioree et leurs utilisations
FR2973704B1 (fr) Composes activateurs des peptidyl-arginine desiminases 1 et/ou 3 dans l'epiderme et leurs utilisations
FI9978U1 (fi) Istutusastia ja istutusjärjestelmä
FR2991561B1 (fr) Dispositif de conditionnement et d'application